Additional Listing

Deltex Medical Group PLC
22 June 2007



                             Deltex Medical Group plc

              Placing of 8,290,029 New Ordinary Shares at 23 pence
                      to raise approximately £1.91 million



22 June 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
UK's leading haemodynamic monitoring company, today announces that Charles
Stanley Securities has, on behalf of the Company, placed 8,290,029 new ordinary
shares of 1 pence each ('New Ordinary Shares') at a price of 23 pence, to raise
approximately £1.91 million before expenses (the 'Placing').

The Company will use the proceeds to significantly expand its manufacturing
capability in response to sales growth of its CardioQ(TM)products in each of its
key markets and to augment working capital. In particular the Company plans to
more than double the maximum production capacity of its existing factory,
automate certain key manufacturing processes relating to production of its
disposable probes, implement new best practice business continuity plans and to
further develop the CardioQ monitor to improve and upgrade its componentry and
functionality. In addition, the Company is strengthening further its
intellectual property by broadening the scope of patents.

Implementation of the Company's plans to expand its manufacturing capacity
follows the announcement on 5 June 2007 confirming national coverage for
reimbursement by the Centers for Medicare and Medicaid Services in the USA with
effect from 22 May 2007.



Deltex Medical's chairman, Nigel Keen, commented:



'Deltex Medical has reached a key stage in its development where it is
experiencing both sustained and sustainable growth in all of its key markets.
Furthermore the Company's potential for future growth has been enhanced
significantly by the recent announcement of reimbursement coverage in the USA.
This investment in the expansion of our manufacturing capacity will allow us to
meet the rising demand for our products.'



Placing details


Charles Stanley has agreed to use its reasonable endeavours to place 8,290,029
New Ordinary Shares on behalf of the Company with institutional and other
investors. The Placing is conditional, inter alia, upon Admission and is
intended to raise approximately £1.91 million, before expenses.

Application will be made for the New Ordinary Shares issued pursuant to the
Placing to be admitted to trading on AIM and it is anticipated that Admission
will become effective and that dealings will commence on Wednesday 27 June 2007.

The Placing is not a rights issue or open offer and New Ordinary Shares will not
be offered generally to Shareholders, whether on a pre-emptive basis or
otherwise. The Directors believe that the considerable extra cost and delay
involved in a rights issue or open offer would not be in the best interests of
the Company in the circumstances.

The Placing Shares will represent approximately 8.97 per cent. of the entire
issued share capital of the Company immediately following Admission. Following
the Placing the Company will have 92,398,470 ordinary shares in issue. This
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or a
change to their interest in Deltex Medical Group plc, under the Disclosure and
Transparency Rules. The Placing Shares will, when issued, rank equally in all
respects with the existing ordinary shares.



Summary of the Placing Agreement



The Company has today entered into a placing agreement with Charles Stanley (the
'Placing Agreement'). The obligations of Charles Stanley under the Placing
Agreement are conditional upon certain conditions having being fulfilled (or
waived), including, inter alia, Admission. The agreement contains certain
representations and warranties by the Company as to the accuracy of the
information contained in this announcement and other matters relating to the
Company and its business which are usual for an agreement of this nature.

The Company has agreed to indemnify Charles Stanley against all losses, costs,
charges and expenses which Charles Stanley may suffer or incur as a result of
carrying out its duties under the Placing Agreement, save to the extent the same
arise by virtue of the fraud, negligence or wilful default of Charles Stanley.

Charles Stanley has certain rights, at any time prior to Admission, to terminate
their obligations under the Placing Agreement in certain limited circumstances.
Such circumstances include, inter alia, material breach by the Company of the
terms of the Placing Agreement or any warranty therein being or becoming untrue,
inaccurate or misleading in any material respect.




For further information, please contact:-


Deltex Medical Group plc                         01243 774 837
Nigel Keen, Chairman                             [e-mail]
Andy Hill, Chief Executive                       [e-mail]
Ewan Phillips, Finance Director                  [e-mail]

Gavin Anderson & Company                         0207 554 1400
Deborah Walter                                   [e-mail]
Robert Speed                                     [e-mail]

Charles Stanley Securities                       020 7149 6457
Philip Davies                                    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-



  • Validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • Proved that the CardioQ works in a wide range of surgical procedures

  • Demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.




                      This information is provided by RNS
            The company news service from the London Stock Exchange